title: Effects of hyperbaric oxygen treatment on horses with experimentally induced endotoxemia.
abstract: OBJECTIVE
  To determine the effectiveness of preinduction hyperbaric oxygen treatment (HBOT) in ameliorating signs of experimentally induced endotoxemia in horses.
  
  
  METHODS
  18 healthy adult horses.
  
  
  METHODS
  Horses were randomly assigned to 1 of 3 equal-sized treatment groups to receive normobaric ambient air and lipopolysaccharide (LPS), HBOT and LPS, or HBOT and physiologic saline (0.9% NaCl) solution. Horses were physically examined, and blood was obtained for a CBC and to determine concentration or activity of plasma tissue necrosis factor-α, blood lactate, and blood glucose before the horses were treated with HBOT and then intermittently for 6 hours after administration of LPS or physiologic saline solution.
  
  
  RESULTS
  All LPS-treated horses developed signs and biochemical and hematologic changes consistent with endotoxemia. Treatment with HBOT significantly ameliorated the effect of LPS on clinical endotoxemia score but did not significantly improve other abnormalities associated with endotoxemia.
  
  
  CONCLUSIONS
  The protective effect of HBOT was minimal, and results did not support its use as a treatment for horses prior to development of endotoxemia.
authors: Department of Large Animal Clinical Sciences, University of Tennessee, Knoxville, TN 37996, USA.
authors: Chad A
authors: CA
authors: Baumwart
authors: Tom J
authors: TJ
authors: Doherty
authors: James
authors: J
authors: Schumacher
authors: Rebekah S
authors: RS
authors: Willis
authors: Henry S
authors: HS
authors: Adair
authors: Barton W
authors: BW
authors: Rohrbach
mesh_terms: D000818:Animals; D001774:Blood Chemical Analysis / Q000662:veterinary; D001831:Body Temperature; D019446:Endotoxemia / Q000628:therapy / Q000662:veterinary*; D005260:Female; D006339:Heart Rate; D006734:Horse Diseases / Q000628:therapy*; D006736:Horses; D006931:Hyperbaric Oxygenation / Q000662:veterinary*; D016018:Least-Squares Analysis; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D010100:Oxygen / Q000097:blood / Q000627:therapeutic use*; D056152:Respiratory Rate; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D010100:Oxygen